by desquamation of palms and soles (Figure). Laboratory tests detected leukopenia and thrombocytopenia. Test results for Plasmodium spp. and dengue virus were negative, and blood culture results were negative as well. By using ELISA, anti-CHIKV IgM antibodies were detected 10 days after onset of symptoms, and anti-CHIKV IgG antibodies (titer 25,600) were detected 8 months later.

Both patients were diagnosed after the viremic period; no virus could be isolated or genotyped. Nevertheless, health authorities were alerted and appropriate control measures were taken.

Travelers can serve as sentinels for the introduction of viruses into previously non–disease-endemic areas. Several reports have been made of travelers carrying CHIKV to and from many regions of the world (2,4–6). Recent identification of the expansion of infested areas by Ae. aegypti and Ae. albopictus mosquitoes, population susceptibility for the virus, and the constant journeying of travelers from affected areas are relevant indications of the risk for introduction and sustained transmission of CHIKV in Brazil.

Health care professionals and public health authorities should be aware of the epidemiologic and clinical aspects of CHIKV infection and diagnoses to adopt prompt control measures to avoid CHIKV transmission in Brazil. Healthcare facilities and epidemiologic surveillance teams have jointly implemented CHIKV prevention and control measures. To date, no autochthonous transmission of CHIKV has been reported in Brazil.

Acknowledgments
We thank the patients for their cooperation. We also thank M. Taciana Sales Oliveira and Rosemeire Silva. In addition, we are grateful to the Adolfo Lutz Institute, the Evandro Chagas Institute, and the Superintendent for Endemic Disease Control of the São Paulo State Department of Health.

Tânia do Socorro Souza Chaves, Alessandra Cristina Guedes Pellini, Melissa Marchetti, Maria Teresa Jahnel, Ana Freitas Ribeiro, Sueli Guerreiro Rodrigues, Pedro Fernando da Costa Vasconcelos, and Marcos Boulos

Author affiliations: University of São Paulo School of Medicine, São Paulo, Brazil (T.S.S. Chaves, M. Boulos); Emilio Ribas Institute of Infectious Diseases, São Paulo (T.d.S.S. Chaves); Center for Epidemiological Surveillance, São Paulo (A.C.G. Pellini, M. Mascheretti, M.T. Jahnel, A.F. Ribeiro); and Evandro Chagas Institute, Belém, Brazil (S.G. Rodrigues, P.F.C. Vasconcelos)

DOI: http://dx.doi.org/10.3201/eid1803.110838

References

Address for correspondence: Tânia do Socorro Souza Chaves, Rua Padre Machado, 584/104 Vila Mariana, CEP 04127 001 São Paulo, Brazil; email: tania.chaves@uol.com.br

Enhanced Surveillance for White-Nose Syndrome in Bats

To the Editor: White-nose syndrome (WNS) is an emerging fungal disease in bats that was first described near Albany, New York, USA, in February 2006 (1). The causative agent, Geomyces destructans, is a psychrophilic (cold-loving) fungus that infects the skin of bats and leads to depletion of their fat stores during hibernation (2). WNS has caused dramatic cumulative mortality rates (up to 99%) in some winter hibernacula and has killed millions of

530 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 3, March 2012
bats among 6 cave-roosting species in 19 central and eastern US states and 4 Canadian provinces (3). In addition, the fungus has been identified in 2 additional US states, although bat deaths have not been associated with it. No evidence has been found that WNS is transmitted from bats to humans, although humans may play a role in translocation of the fungus between caves (4,5).

Current surveillance for WNS is time- and labor-intensive. Wildlife personnel typically enter caves, inspect hibernacula, and collect bats with clinically compatible signs for testing (4). In July 2010, the National Park Service (NPS) Office of Public Health proposed an expanded WNS surveillance strategy that involved using opportunistic sampling of bats already submitted to state public health laboratories for rabies testing; the bats submitted include species known to be susceptible to WNS. The pilot study focused on the region around Mammoth Cave National Park, the world’s longest known cave system and home to 13 bat species (2 endangered), in south-central Kentucky (6). At the time of initial discussions, Kentucky was WNS-free, but the bordering state of Tennessee had recently reported its first WNS cases in spring 2010 in a cave system located <130 km from Mammoth Cave. WNS was first detected in Kentucky in April 2011 in Trigg County (180 km from Mammoth Cave) (7).

The goals of this pilot study were to 1) enhance WNS surveillance in counties in and near Mammoth Cave and 2) demonstrate a feasible, cost-effective surveillance system. NPS Office of Public Health staff coordinated meetings in Kentucky and Tennessee with representatives from the state departments of wildlife and health and other partnering organizations. Key representatives at one or both of these meetings included the state epidemiologist, the state public health veterinarian, the public health laboratory director, state wildlife biologists, and NPS and state wildlife veterinarians. Also attending both meetings was a veterinary pathologist from the Southeastern Cooperative Wildlife Disease Study (SCWDS) in Athens, Georgia, USA, one of 3 laboratories that test most samples for WNS in the United States. The surveillance concept was well received in both states, and state-specific protocols were developed for submitting rabies-negative bats to SCWDS only during hibernation months (November–April) when WNS is more likely to be detected (8). In Kentucky, a memorandum of understanding was drafted that outlined roles and responsibilities of collaborating agencies. The memorandum was reviewed by legal advisors and signed by public health and wildlife officials.

Both protocols outlined key elements of the submission process, including how laboratory personnel were to submit rabies-negative bats to SCWDS for WNS testing (fungal culture, histopathologic examination, and PCR), how bats were to be stored or destroyed after testing, and the chain of communication for reporting test results. Whenever possible, bats were frozen at −20°C within 48 hours following rabies testing, and their muzzles and forearms were left intact to maximize the yield for G. destructans and to facilitate species identification. Protocols included additional criteria to improve testing efficiency (e.g., prioritizing submissions on the basis of known WNS-susceptible species or counties where cave-roosting colonies are located). A project-specific version of the standard SCWDS submission form was completed for all samples. All funding and resources were provided in kind by respective agencies.

In October 2010, the Tennessee State Public Health Laboratory submitted 34 rabies-negative bats (archived during January–April 2010, before pilot study discussions) from 18 counties to SCWDS; all were WNS-negative. Twenty-one additional rabies-negative bats from 9 Tennessee counties collected during November 2010–April 2011 also tested negative for WNS. In Kentucky, 64 rabies-negative bats (from 22 counties) were submitted during November 2011–January 2012; all were WNS-negative except 1 bat tested on January 13, 2012, which was the first known WNS-positive bat from Fayette County, a primarily urban area in northern central Kentucky where little cave-based WNS surveillance is conducted. Overall, although the sample of bats tested to date is modest and likely insufficient as a stand-alone surveillance system, these results supplement other data and can inform the development of interventions, prevention messages, and transmission models.

This pilot study highlights several observations and implications. First, it demonstrates that opportunistic testing of rabies-negative bats for WNS can be facilitated between state departments of wildlife and health through interagency collaboration. Second, the surveillance system is low cost and could potentially be expanded to other states where WNS is likely to emerge and where statewide cave-based surveillance is cost-prohibitive. Last, this project showcases a unique interdisciplinary collaboration in wildlife and human health, disease ecology, and environmental stewardship. Such partnerships are championed by the One Health approach (9) and are central to the mission of NPS to protect the health of all species and our environment (10).

Acknowledgments

We thank the following persons who contributed considerable time and expertise toward developing this unique collaboration and pilot surveillance program: Coy Ainsley, Roger Applegate, Mike Armstrong, Robyn Atkinson, Sean

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 3, March 2012

Funding for this work was provided, in part, by cooperative agreements between SCWDS and the Tennessee Wildlife Resources Agency and the Kentucky Department of Fish and Wildlife Resources. A.G. was supported through the NPS volunteer epidemiologist-in-residence program.

Anne Griggs, M. Kevin Keel, Kevin Castle, and David Wong

Author Affiliations: National Park Service, Mammoth Cave, Kentucky, USA (A. Griggs); Southeastern Cooperative Wildlife Disease Study, Athens, Georgia, USA (M.K. Keel); National Park Service, Ft. Collins, Colorado, USA (K. Castle); and National Park Service, Albuquerque, New Mexico, USA (D. Wong)

DOI: http://dx.doi.org/10.3201/eid1803.111751

References


Address for correspondence: David Wong, National Park Service, Office of Public Health, 801 Vassar Dr NE, Albuquerque, NM 87106, USA; email: david_wong@nps.gov

NDM-1-producing Klebsiella pneumoniae, Croatia

To the Editor: The novel metallo-β-lactamase named New Delhi metallo-β-lactamase (NDM-1) was identified from Klebsiella pneumoniae and Escherichia coli isolates in Sweden from a patient previously hospitalized in India (1). NDM-1 is spreading rapidly worldwide to nonclinically related isolates, many of which are directly or indirectly tracked to the Indian subcontinent (2). A carbapenem-resistant K. pneumoniae strain, KZLA, was isolated in May 2009 from the culture of a blood sample from a 40-year-old man on the day after his admission to a surgical intensive care unit of the Clinical Hospital Center in Zagreb, Croatia. The patient had been transferred after 5 days of hospitalization in Bosnia and Herzegovina following a car accident. The clinical history mentioned antimicrobial drug treatment that did not include carbapenems (gentamicin, meropenem, and ceftriaxone) and no link to the Indian subcontinent. Antimicrobial drug susceptibility testing was performed by Vetek2 (bioMérieux, Marcy-l’Etoile, France) and broth microdilution and interpreted according to the latest documents from the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org/clinical_breakpoints/, version 1.1).

The strain proved resistant to imipenem and meropenem, to all broad-spectrum cephalosporins, and to aminoglycosides and susceptible to ciprofloxacin and tigecycline (Table). We checked for bla_vim, bla_imp, bla_spm, bla_sim, and bla_NDM resistance genes by using PCR. A PCR product was obtained only with the NDM primers, after being purified (QIAquick PCR Purification Kit, QIAGEN, Hilden, Germany), its sequence showed 100% identity with bla_NDM-1. Strain genotyping was performed by multilocus sequence typing to determine the sequence type (ST) of the isolate and to establish a comparison with previously reported NDM-1-producing isolates. Allelic numbers were obtained on the basis of sequences of 7 housekeeping genes at www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.